CTLA4 and hepatocellular carcinoma: The immune system of affected individuals has an important role in the malignant transformation, and is nowadays the target of various checkpoint inhibitors (for example PD-L1 or CTLA-4) as part of adjuvant or neoadjuvant therapeutic strategies for hepatocellular carcinoma (HCC) (Lee et al. 2020; Finn et al. 2020).